The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road
Dendritic cells (DCs) are recognized as highly potent antigen-presenting cells that are able to stimulate cytotoxic T lymphocyte (CTL) responses with antitumor activity. Consequently, DCs have been explored as cellular vaccines in cancer immunotherapy. To that end, DCs are modified with tumor antige...
Main Authors: | Cleo Goyvaerts, Karine Breckpot |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02052/full |
Similar Items
-
Dendritic Cell Cancer Vaccines: From the Bench to the Bedside
by: Tamar Katz, et al.
Published: (2014-10-01) -
Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
by: Alexey V. Baldin, et al.
Published: (2020-03-01) -
Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
by: Ahmed Salah, et al.
Published: (2021-06-01) -
Dendritic Cell-Induced Th1 and Th17 Cell Differentiation for Cancer Therapy
by: Julia Terhune, et al.
Published: (2013-11-01) -
Expression of tolerogenic potential-representing markers on clinical-grade therapeutic dendritic cell-based cancer vaccines
by: Neringa T. Dobrovolskienė, et al.
Published: (2014-02-01)